Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9238657 | SHIONOGI INC | Cephalosporin having catechol group |
Nov, 2033
(10 years from now) | |
US10004750 | SHIONOGI INC | Salt of cephalosporin derivative, its crystalline solid and a method of manufacturing thereof |
Sep, 2035
(12 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9949982 | SHIONOGI INC | Preparation containing cephalosporin having a catechol moiety |
Sep, 2035
(12 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Nov 14, 2024 |
New Indication (I) | Sep 25, 2023 |
Generating Antibiotic Incentives Now (GAIN) | Nov 14, 2029 |
NCE-1 date: November, 2028
Market Authorisation Date: 14 November, 2019
Treatment: Method of treating bacterial infections
Dosage: POWDER;INTRAVENOUS
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic